BioPharma Dive September 17, 2024
Backed by Bristol Myers Squibb, Ratio Therapeutics has a front row seat to the pharmaceutical industry’s pivot into the field of targeted radiation drugs.
As far as cancer treatments go, radiopharmaceuticals are conceptually simple. After all, radioactive isotopes are very good at killing cancer cells. And as targeting technology improves, large pharma companies are paying closer attention to the drug field and the many smaller biotechnology firms within it.
This radio-renaissance belies the long history of radiation-based drugs, the idea for which has been around for more than half a century, said Jack Hoppin, CEO of Ratio Therapeutics, one of those small biotechs.
“It’s not a novel concept to put a radioisotope into patients,” Hoppin said, describing research into the...
Today's Sponsors
Today's Sponsor